The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy

Journal of the American Society of Nephrology

Volumn 7, Issue 11, 1996, Pages 2434-2444

  Nakamura, Takamichi ^a,d   Tanaka, Nobuko ^b   Higuma, Norio ^b   Kazama, Takashi ^c   Kobayashi, Lsao ^a   Yokota, Sadaki ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b NIIGATA CITY GENERAL HOSPITAL   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

^d UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Membranous nephropathy; PAI 1; Vitronectin

Indexed keywords

ARGININE; FIBRINOGEN; GLYCINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VITRONECTIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GLOMERULUS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; KIDNEY DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

EID: 0030363842     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Ehrenreich T, Churg J: Pathology of membranous nephropathy. Pathol Ann 1968;3:145-186.
2. Oomura A, Nakamura T, Arakawa M, Isemura M, Ooshima A: Alterations in the extracellular matrix component in human glomerular diseases. Virchows Arch A Pathol Anat Histopathol 1989;415:151-159.
3. Killen PD, Melcion C, Bonadio JF, Morel-Maroger L, Striker GE: Glomerular response to immunologie injury, studies on progression. Springer Semin Immunopathol 1982;5:297-320.
4. Fogel MA, Boyd CD, Leardkamolharn V, Abrahamson DR, Minto AWM, Salant D: Glomerular basement membrane expansion in Heymann nephritis: Absence of increased synthesis of type IV collagen, laminin, or fibronectin. Am J Pathol 1991;138:465-475.
5. Floege J, Johnson RJ, Gordon K, et al.: Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy. Kidney Int 1992;42:573-585.
6. Shemesh O, Ross JC, Deen WM, Grant GW, Myers BD: Nature of the glomerular capillary injury in Human membranous nephropathy. J Clin Invest 1986;77:868-877.
7. Kanalas JJ, Makker SP: Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen. J Biol Chem 1991;266:10825-10829.
8. Kanalas JJ: Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330. Arch Biochem Biophys 1992; 299:255-260.
9. Kanalas JJ, Makker SP: Isolation of a 330-kDa glycoprotein from human kidney similar to the Heymann nephritis autoantigen (gp330). J Am Soc Nephrol 1990;1:792-798.
10. Quigley JP, Gold LI, Schwimmeer R, Sullivan LM: Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells. Proc Natl Acad Sci USA 1987;84:2776-2780.
11. Liotta LA, Goldfarb RH, Terranova VP: Cleavage of laminin by thrombin and plasmin: alpha thrombin selectively cleaves the beta chain of laminin. Thromb Res 1981;21:663-673.
12. Moscatelli D, Jaffe E, Rifkin DB: Tetradecanoyl phorbol acetate stimulates latent collagenase production by cultured human endothelial cells. Cell 1980;20:343-351.
13. Sappino A-P, Huarte J, Vassalli J-D, Belin D: Sites of urokinase and tissue-type plasminogen activators in the murine kidney. J. Clin Invest 1991;87:962-970.
14. Tomooka S, Border WA, Marshall BC, Noble N: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 1992;42:1462-1469.
15. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ: Cloning and sequence of a cDNA coding for the human β-migrating endothelial-cell type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986;83:6776-6780.
16. Pannekoek H, Veerman H, Lambers H, et al.: Endothelial plasminogen activator inhibitor (PAI): a new member of serpin gene family. EMBO J 1986;5:2539-2544.
17. Kruithof EK, Tran-Thang C, Ransijn A, Bachmann F: Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984;64:907-913.
18. Iwamoto T, Nakashima Y, Sueishi K: Secretion of plasminogen activator and its inhibitor by glomerular epithelial cells. Kidney Int 1990;37:1466-1476.
19. Lacave R, Rondeau E, Ochi S, Delarue F, Scheuning WD, Sraer JD: Characterization of a plasminogen activator and its inhibitor in human mesangial cells. Kidney Int 1989;35:806-811.
20. Preissner KT, Grulich-Henn J, Ehrlich HL, et al.: Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990;265: 18490-18498.
21. Tomasini BR, Mosher DF: On the identity of vitronectin and S-protein: Immunological crossreactivity and functional studies. Blood 1986;68:737-742.
22. Tschopp J, Masson D, Schafer S, Peitsch M, Preissner KT: The heparin binding domain of S-protein/Vitronectin binds to compements C7,C8, and C9 and perform from cytolytic T-cells and inhibits their lytic activities. Biochemistry 1988;27:4103-4109.
23. Bariety J, Hinglais N, Bhakdi S, Mandet C, Rouchon M, Kazatchkine MD: Immunohistochemical study of complement S protein (Vitronectin) in normal and diseased human kidneys: Relationship to neoantigens of the C5b-9 terminal complex. Clin Exp Immunol 1989;75: 76-81.
24. Falk RJ, Podack E, Dalmasso AP, Jennette JC: Localization of S-protein and its relationship to the membrane attack complex of complement in renal tissue. Am J Pathol 1987;127:182-190.
25. Lai KN, Lo STH, Lai FM-M: Immunohistochemical study of the membranous attack complex of complement and S-protein in idiopathic and secondary membranous nephropathy. Am J Pathol 1989;135:469-476.
26. Keeton M, Eguchi Y, Sawdey M, Ahn CC, Loskutoff DJ: Cellular localization of type-1 plasminogen activator inhibitor mRNA and protein in murine renal tissue. Am J Pathol 1993;142:59-70.
27. Keeton M, Ahn C, Eguchi Y, Burligame R, Loskutoff DJ: Expression of type-1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis. Kidney Int 1995; 47:148-157.
28. Rondeau E, Mougenot B, Lacave R, Peraldi MN, Kruithof EKO, Sraer JD: Plasminogen activator inhibitor- 1 in renal fibrin deposits of human nephropathies. Clin Nephrol 1990;33:55-60.
29. Aya N, Yoshioka K, Murakami K, Hino S, Okada K, Matsuo O, Maki S: Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis. J Pathol 1992;166:289-295.
30. Yokota S, Hirose A, Mizugaki M: Immunocytochemical localization of 2,4-dienoyl-CoA reductase in the liver of normal and di-(2-ethylhexyl)phthalate-fed rats. Histochem J 1988;20:679-687.
31. Nakamura T: Monoclonal antibodies to human glomerular antigens. II. Using human adult kidney components as antigens. Clin Immunol Immunopathol 1986;41:399-408.
32. Nakamura T, Oite T, Kazama T, et al.: Monoclonal antibodies to human glomerular antigens. Virchows Arch A Pathol Anat Histopathol 1988;412:573-582.
33. Mimuro J, Schleef RR, Loskutoff DJ: Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 1987;70:721-728.
34. Yokota S: Cytochemical and imrnunocytochemical study on the peroxisomes of rat liver after administration of a hypolipidemic drug, MLM-160. Eur J Cell Biol 1990;53: 112-121.
35. De Roe C, Courtoy PJ, Baudhuin H: A model of protein-A colloidal gold interactions. J Histochem Cytochem 1987; 35:1191-1198.
36. Yokoto S: Quantitative immunocytochemical studies on differential induction on serine pyruvate aminotransferase in mitochondria and peroxisomes of rat liver cells by administration of glucagon or di-(2-ethylhexyl)phthalate. Histochemistry 1986;85:145-155.
37. Bendayan M, Roth J, Pereletet A, Orci L: Quantitative imrnunocytochemical localization of pancreatic secretory proteins in subcellular compartments of the rat acinar cell. J Histochem Cytochem 1980;28:149-160.
38. Nakamura T, Miller D, Ruoslahti E, Border WA: Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-β1. Kidney Int 1992;41:1213-1221.
39. Bergstein JM, Michael AF: Cortical fibrinolytic activity in normal and diseased human kidney. J Lab Clin Med 1972;79:701-709.
40. Dano K, Ahdreasen PA, Grondahl-Hansen J, Kristensen P, Noelsen LS, Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-239.
41. Angles-Cano E, Rondeau E, Delarue F, Hagege J, Sultan Y, Sraer JD: Identification of cellular localization of plasminogen activators from human glomeruli. Thromb Haemostasis 1985;54:688-692.
42. Nakamura T, Yokota S, Tanaka N, Honma H, Kuroyanagi R, Tamura K: The possible role of fibrinolytic system in the thickening of the GBM seen in Heymann nephritis [Abstract]. J Am Soc Nephrol 1992;3:607.
43. Stack S, Gonzales-Gronow M, Pizzo SV: Regulation of plasminogen activation by components of the extracellular matrix. Biochemistry 1990;29:4966-4970.
44. Knudsen BS, Silverstein RL, Leung LLK, Harpel PC, Nachman RL: Binding of plasminogen to extracellular matrix. J Biol Chem 1986;261:10765-10771.
45. Moser TL, Enghild JJ, Pizzo SV, Stack MS: The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J Biol Chem 1993;268:18917-18923.
46. Kooista T, Sprengers ED, Van Hinsberg VWM: Rapid inactivation of the plasminogen-activator inhibitor upon secretion from cultured human endothelial cells. Biochem J 1986;239:497-503.
47. Mimuro J, Loskutoff DJ: Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem 1989;264:936-939.
48. Ciambrone GJ, McKeown-Longo PJ: Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells. J Cell Biol 1990;111:2183-2195.